MedTrace Logo

Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

NCT04463771 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 206

Last updated 2025-12-10

No results posted yet for this study

Summary

This is a multicenter, open-label, nonrandomized, Phase 2 umbrella study of retifanlimab in participants who have advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy. retifanlimab will be administered as monotherapy or in combination with other immunotherapy or targeted agents.

Conditions

Interventions

DRUG

retifanlimab

INCMGA00012 administered intravenously on Day 1 of each 28-day cycle for up to 26 cycles.

DRUG

epacadostat

epacadostat will be administered orally BID.

DRUG

pemigatinib

pemigatinib will be administered orally QD.

DRUG

INCAGN02385

INCAGN2385 will be administered every 2 weeks

DRUG

INCAGN02390

INCAGN2390 will be administered every 2 weeks

Sponsors & Collaborators

  • GOG Foundation

    collaborator NETWORK

  • European Network of Gynaecological Oncological Trial Groups (ENGOT)

    collaborator OTHER

  • Incyte Corporation

    lead INDUSTRY

Principal Investigators

  • Mark Cornfield · Incyte Corporation

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-26
Primary Completion
2026-04-14
Completion
2026-07-10
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • France
  • Georgia
  • Germany
  • Greece
  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04463771 on ClinicalTrials.gov